Department of Neurosurgery, Thomas Jefferson University, United States.
Department of Neurology, University of Alabama, United States.
Clin Neurol Neurosurg. 2020 Oct;197:106177. doi: 10.1016/j.clineuro.2020.106177. Epub 2020 Aug 22.
Data suggest that elderly patients have less favorable outcomes after ischemic stroke.
To study the outcomes after intravenous tissue plasminogen activator (tPA) administration in elderly patients with acute ischemic stroke.
Cross-sectional study using prospective collected patient data maintained via our "tele-stroke" network, which provides acute care in 29 community hospitals within our region from 2013-2015. Exposure of interest was age divided into >80 years (octogenarian) or younger. Outcomes of interest were rate of intravenous tPA administration, hemorrhagic transformation (ICH), in-hospital neurological deterioration, and poor outcome defined as a composite of hospital discharge to long-term care facility or death.
Mean age 67 ± 16 years, 57 % (743/1317) were women, and median (Md) NIHSS was 4 (Interquartile Range [IQR] 8). The rate of tPA was 20 % (267/1317). Compared to reported rates of tPA administration in the nation, our tPA rate exceeded the one from the literature (20 % v 3%, z = 2.83, SE = 0.04, p = .005). There were no differences in ICH or neurological deterioration. The octogenarian group had a higher proportion of poor-outcome (61 % vs. 23 %, p < 0.001) than the younger group but similar in-hospital case-fatality (25 % v 14 %, p = 0.09). Predictors of poor-outcome were age >80 (OR 4.9; CI, 2.0-12, p < .001) and α-NIHSS>9. (OR 8.7; CI, 3.5-20, p < .001).
Our data suggest that in our "tele-stroke" network, rates of tPA administration are higher than those reported in the literature and that this rate was not different in octogenarians compared to younger patients. Octogenarians were not at risk for ICH or neurological deterioration after tPA administration. However, octogenarians had a higher risk of poor outcome.
数据表明,老年患者在发生缺血性卒中后预后较差。
研究急性缺血性卒中老年患者静脉注射组织型纤溶酶原激活剂(tPA)后的结局。
使用前瞻性收集的患者数据进行横断面研究,这些数据通过我们的“远程卒中”网络获取,该网络自 2013 年至 2015 年为我们地区的 29 家社区医院提供急性护理。感兴趣的暴露因素为年龄,分为>80 岁(80 岁以上)或<80 岁。感兴趣的结局包括静脉 tPA 给药率、出血性转化(ICH)、住院期间神经功能恶化以及不良结局(定义为出院至长期护理机构或死亡的复合结局)。
平均年龄 67±16 岁,57%(743/1317)为女性,NIHSS 中位数(Md)为 4(四分位距 [IQR] 8)。tPA 使用率为 20%(267/1317)。与全国范围内报告的 tPA 使用率相比,我们的 tPA 使用率高于文献报道(20%比 3%,z=2.83,SE=0.04,p=0.005)。ICH 或神经功能恶化无差异。80 岁以上组不良结局的比例更高(61%比 23%,p<0.001),但院内病死率相似(25%比 14%,p=0.09)。不良结局的预测因素为年龄>80 岁(OR 4.9;95%CI,2.0-12,p<0.001)和α-NIHSS>9(OR 8.7;95%CI,3.5-20,p<0.001)。
我们的数据表明,在我们的“远程卒中”网络中,tPA 给药率高于文献报道,80 岁以上患者与年轻患者相比,tPA 给药率无差异。80 岁以上患者在 tPA 治疗后ICH 或神经功能恶化的风险并未增加。然而,80 岁以上患者发生不良结局的风险更高。